A soon-to-be published guideline from the ACR and the Vasculitis Foundation on Kawasaki disease underscores the importance of early diagnosis and intensified treatment for people with this serious condition.1 Intravenous immunoglobulin (IVIG) remains the treatment mainstay, and prompt, aggressive treatment may be able to reduce the risk of serious complications in some patients. The guideline…
Experts shined a spotlight on select abstracts of the latest rheumatology research, addressing such topics as racial disparities in the management of children with SLE, vitamin D or fish oil supplementation to prevent autoimmune disease & more.
New concepts in autoimmunity & immunology are being discovered daily in research being conducted to understand the SARS-CoV-2 virus and its implications for rheumatology & all fields of medicine. Here are some insights shared by experts during day 1 of the Basic and Clinical Research Conference.
Recognition as an ACR Master is one of the highest honors the College bestows. The designation of Master is conferred on ACR members, age 65 or older by Oct. 1 of the year in which they are nominated, who have made outstanding contributions to the ACR and the field of rheumatology through scholarly achievement and/or…
During ACR Convergence 2021 in early November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the winners of the ARP President’s and Merit Awards. ARP PRESIDENT’S AWARDS The ARP president can choose to honor ACR/ARP…
Diversity, equity and inclusion (DEI) are the focus of a new ACR/ARP subcommittee of the Collaborative Initiatives (COIN) Special Committee. The 13-member group will explore strategies to increase diversity in the rheumatology workforce pipeline and reduce implicit bias in such organizational processes as speaker recruitment and abstract review. “There is a new awareness at the…
Amid spirited discussions on drug pricing and insurance challenges, participants got hands-on experience advocating for current bills regulating prior authorization and pharmacy benefit managers.
NEW YORK (Reuters Health)—Pediatric rheumatologists and nephrologists appear to differ in their treatment choices for children who have lupus nephritis (LN), with rheumatologists more likely to prescribe rituximab, results of a small survey suggest. “This study highlights the importance of collaborative effort in developing CTPs (Consensus Treatment Plans) for pediatric LN,” the authors write in…
Janus kinase 1 and 2 inhibitors (jakinibs) have been approved for the treatment of rheumatoid arthritis, psoriatic arthritis and, most recently, juvenile idiopathic arthritis. They have also shown promise in the treatment of interferon (IFN) mediated diseases. The Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway is the principal signaling pathway for…
The group’s goals include workforce diversification and inclusive speaker recruitment.